Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Sheryl Koski"'
Publikováno v:
Future Oncology. 18:47-54
Aims: To review the patterns of early-onset (
Publikováno v:
International Journal of Colorectal Disease
Objective To assess the patterns of hospitalizations among early-stage colon cancer patients receiving adjuvant chemotherapy and to identify high-risk groups that may benefit from more careful monitoring in a real-world, population-based context. Met
Publikováno v:
International Journal of Colorectal Disease. 36:493-499
To assess the real-world patterns of systemic treatment attrition rates among patients with metastatic colorectal cancer. Databases based from the provincial cancer registry and electronic medical records in Alberta were accessed, and cases with a de
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 146:2089-2097
To evaluate the patterns of vitamin and herbal supplement use among patients with advanced gastrointestinal (GI) cancers and the association of such behavior with the efficacy and toxicity of systemic anticancer treatment. Project data sphere (PDS) w
Autor:
Omar Abdel-Rahman, Sheryl Koski
Publikováno v:
Neuroendocrinology. 112(8)
Objective: This study aimed to assess the survival differences between cisplatin/etoposide versus carboplatin/etoposide chemotherapy regimens in the management of patients with extrapulmonary neuroendocrine carcinomas (NECs). Methods: Administrative
Publikováno v:
Medical Oncology. 38
The aim of the study was to analyze the real-world treatment patterns of adjuvant chemotherapy administration among patients with resected pancreatic adenocarcinoma. Cases with non-metastatic pancreatic adenocarcinoma, diagnosed 2007-2018, treated wi
Autor:
Yuan Gao, Sheryl Koski, Timothy J. Price, Atsushi Ohtsu, John Simes, Matthew Hitron, Christopher O'Callaghan, Wei Li, Derek J. Jonker, Dongsheng Tu, Nadine M Magoski, Michael M Vickers, Sharlene Gill, Chiang J Li, Alice C. Wei, Jeremy Shapiro, John Zalcberg, Louise M. Nott, Taito Esaki, Takayuki Yoshino, Youzhi Li, Niall C. Tebbutt, Ben Markman
Publikováno v:
The Lancet Gastroenterology & Hepatology. 3:263-270
Summary Background Napabucasin is a first-in-class cancer stemness inhibitor that targets STAT3, which is a poor prognostic factor in colorectal cancer. This study aimed to test napabucasin in advanced colorectal cancer. Methods This study was a doub
Autor:
Bruce Colwell, John R. Goffin, Hagen F. Kennecke, B. Samson, Félix Couture, Setareh Samimi, Tahir Abbas, Francine Aubin, Scott R. Berry, Alice C. Wei, Dongsheng Tu, Sheryl Koski, Nadine M Magoski, Petr Kavan, Chaudhary E. Ahmad, Jonathan M. Loree, Mohammed Harb, Christopher J. O'Callaghan, Nathalie Aucoin, Eric Chen, Derek J. Jonker
Publikováno v:
JAMA Oncology. 6:831
Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than in those patients who are microsatellite-instability high (MSI-H).To evaluate whether combining programmed death-ligand 1 (P
Autor:
Duc Le, Shahid Ahmed, C. Doll, J P McGhie, Pamela Hebbard, Sheryl Koski, E. Jones, Hagen F. Kennecke, Scott R. Berry, K.T. Tan, V Gordon, D. Buie, M. Krahn, Karen E. Mulder, S. Dowden, Cecilia Margareta Lund, Raimond Wong, Jason Park, O. Bathe, Janine M. Davies, A. Mcffadden, F. Rashidi, Yigang Luo, Sharlene Gill, Howard John Lim, Amer Sami
Publikováno v:
Current Oncology. 22:113-123
The 16th annual Western Canadian Gastrointestinal Cancer Consensus Conference was held in Saskatoon, Saskatchewan, September 4–5, 2014. The Consensus Conference is an interactive, multidisciplinary event attended by health care professionals from a
Autor:
Alice Chia-chi Wei, Félix Couture, Derek J. Jonker, Hagen F. Kennecke, Chaudhary E. Ahmad, Eric Chen, Jonathan M. Loree, Tahir Abbas, Christopher J. O'Callaghan, Mohammed Harb, Benoit Samson, Setareh Samimi, Scott R. Berry, John R. Goffin, Francine Aubin, Sheryl Koski, Dongsheng Tu, Bruce Colwell, Nathalie Aucoin, Petr Kavan
Publikováno v:
Journal of Clinical Oncology. 37:3512-3512
3512 Background: Targeting both PD-L1 and CTLA-4 may be synergistic immunotherapy approaches. CO.26 evaluated if dual inhibition leads to improved pt survival vs BSC alone in rmCRC. Methods: rmCRC pts were randomized 2:1 to D+T vs BSC. Treatment cons